Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo, Paolo Chiodini, Maria Riemma, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6400-6400
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update
Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 35, pp. 3959-3977
Open Access | Times Cited: 125
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Nicola Fusco, Umberto Malapelle, Matteo Fassan, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 104
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 16, pp. 3549-3563
Open Access | Times Cited: 34
Targeting Autophagy in Breast Cancer
Stefania Cocco, Alessandra Leone, Michela Piezzo, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7836-7836
Open Access | Times Cited: 78
CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies
Nadia Harbeck, Meaghan Bartlett, Dean Spurden, et al.
Future Oncology (2021) Vol. 17, Iss. 16, pp. 2107-2122
Open Access | Times Cited: 61
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study
RK Goyal, Hua Chen, Susan Abughosh, et al.
Cancer (2023) Vol. 129, Iss. 7, pp. 1051-1063
Closed Access | Times Cited: 37
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy
Qitong Wu, Dipali Sharma
Cells (2023) Vol. 12, Iss. 8, pp. 1156-1156
Open Access | Times Cited: 31
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Mandy Lawson, Natalie Cureton, Susana R�os, et al.
Cancer Research (2023) Vol. 83, Iss. 23, pp. 3989-4004
Open Access | Times Cited: 30
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Wanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 10
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
Mariia Ivanova, Francesca Porta, Federica Giugliano, et al.
Genes (2023) Vol. 14, Iss. 6, pp. 1160-1160
Open Access | Times Cited: 19
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
Dongqing Pu, Debo Xu, Yue Wu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 7
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
Francisco Cézar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 5, pp. 464-464
Open Access | Times Cited: 7
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Fernand Bteich, Mahshid Mohammadi, T. Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12030-12030
Open Access | Times Cited: 14
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
Matti Poutanen, Malin Hagberg Thulin, Pirkko Härkönen
Nature reviews. Cancer (2023) Vol. 23, Iss. 10, pp. 686-709
Closed Access | Times Cited: 12
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, et al.
Breast Cancer Research and Treatment (2024) Vol. 204, Iss. 3, pp. 579-588
Open Access | Times Cited: 4
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
Ye Hu, Fengxi Chen, Siwen Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, et al.
The Breast (2024) Vol. 75, pp. 103729-103729
Open Access | Times Cited: 4
Molecular changes driving low-grade serous ovarian cancer and implications for treatment
Lucy Kelliher, Roni Yoeli‐Bik, Lisa Schweizer, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 10, pp. 1630-1638
Closed Access | Times Cited: 4
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer
Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Breast Cancer Research and Treatment (2025)
Open Access
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer
Reiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, et al.
Breast Cancer (2025)
Closed Access
Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study
Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patrícia Ribeiro Portella de Araújo, et al.
Journal of Chemotherapy (2025), pp. 1-10
Closed Access
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
Elisabetta Munzone, Eleonora Pagan, Vincenzo Bagnardi, et al.
ESMO Open (2021) Vol. 6, Iss. 6, pp. 100332-100332
Open Access | Times Cited: 25
Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer
Matthew G. Davey, Éanna J. Ryan, Peter McAnena, et al.
Surgical Oncology (2021) Vol. 37, pp. 101531-101531
Closed Access | Times Cited: 24
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?
Linda Cucciniello, Lorenzo Gerratana, Lucia Del Mastro, et al.
Cancer Treatment Reviews (2022) Vol. 110, pp. 102445-102445
Open Access | Times Cited: 18
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
Carlo Palmieri, A. E. Musson, Catherine Harper‐Wynne, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 5, pp. 852-860
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top